Vanguard Capital Management
NMTC icon

Vanguard Capital Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Vanguard Capital Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
352,774
+119,886
+51% +$490K ﹤0.01% 3582
2026
Q1 		$1.09M Buy
+232,888
New +$1.12M ﹤0.01% 3529

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's NMTC Position: Q2 2026 in Review

Vanguard Capital Management increased its NeuroOne Medical Technologies (NMTC) stake by 51% in Q2 2026, buying an estimated $490K and bringing the position to 352,774 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

Vanguard Capital Management first reported a position in NMTC in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.09M in Q1 2026. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • Vanguard Capital Management held 352,774 shares of NeuroOne Medical Technologies worth $1.07M as of Q2 2026.
  • Vanguard Capital Management bought 119,886 NeuroOne Medical Technologies shares in Q2 2026, an estimated $490K.
  • NeuroOne Medical Technologies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3582 holding.
  • Vanguard Capital Management first reported a position in NeuroOne Medical Technologies in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's NeuroOne Medical Technologies position peaked at $1.09M in Q1 2026.
  • 27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.